Views & Analysis | Perspectives on pharma industry issues

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

R&D

Closed & Collaborative – January to February 2026

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

Oncology

ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si

Patients

Healthcare report finds declining public trust in institutio...

There are few things more important than health, but a recent report suggests that the public has declining trust in traditional healthcare institutions to protect theirs.

Patients

Houses of Parliament - a Labour government

Labour, the NHS, and life sciences: Partnerships and people

The United Kingdom this morning woke to landslide poll results: Labour is in on just 34% of the vote following the worst Conservative defeat in the party’s history.

Sales & Marketing

Sponsored

12 Questions with Steve Sanghera

Steve Sanghera is the CEO and co-founder of Inventus.

Sales & Marketing

When women thrive, we all rise

We need to see advancing women as an intentional multiplication that benefits teams, organisations, and communities.

Digital

Why siloed data is stalling the future of smarter healthcare

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today.

Digital

Sponsored

STEM AI: A new lens on data-led field team performance

The relationship between pharmaceutical field teams and healthcare professionals (HCPs) is evolving rapidly.

Market Access

JPM 2026: What it revealed about biotech’s new reality

JPM 2026 signalled genuine recovery – but not the kind the industry has historically celebrated.

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology